Pharmacovigilance area of interest | ||||||
---|---|---|---|---|---|---|
Activity type | Adverse events | Counterfeit drugs | Drug quality assurance | PV NOS | NA | Total |
Behaviour change communication | 3 (100) | 3 (3.2) | ||||
Improve regulatory system | 1 (16.7) | 1 (16.7) | 2 (33.3) | 2 (33.3) | 6 (6.3) | |
Improving supply chain | 1 (25.0) | 3 (75.0) | 4 (4.2) | |||
Laboratory supplies and training | 2 (14.3) | 7 (50.0) | 5 (35.7) | 14 (14.7) | ||
Operations research | 1 (100) | 1 (1.1) | ||||
Pharmacovigilance NOS | 1 (11.1) | 8 (88.9) | 9 (9.5) | |||
Surveillance | 1 (6.3) | 4 (25.0) | 10 (62.5) | 1 (6.3) | 16 (16.8) | |
Training/capacity building | 1 (50.0) | 1 (50.0) | 2 (2.1) | |||
Surveillance-not funded | 3 (100) | 3 (3.2) | ||||
Pharmacovigilance NOS-unfunded | 17 (100) | 17 (17.9) | ||||
Context onlya | 3 (100) | 3 (3.2) | ||||
Historical activityb | 6 (25.0) | 11 (45.8) | 5 (20.8) | 2 (8.3) | 24 (25.3) | |
Total | 5 (5.3) | 18 (18.9) | 57 (60.0) | 13 (13.7) | 5 (5.3) | 95 (100) |